Klaria Interim Report
Klaria Pharma Holding AB Interim Report Q2 2020
Substantial progress in both of Klaria’s leading development projects
SECOND QUARTER OF 2019
∞∞Net sales 0.1 MSEK (0.0 MSEK)
∞∞R&D costs for the period amounted to 4.3 MSEK (8.2 MSEK)
∞∞Profit after tax amounted to -7.9 MSEK (-9.3 MSEK)
∞∞Earnings per share for the quarter amounted to -0.26 SEK (-0.30 SEK)
∞∞Cash flow from operating activities amounted to -4.3 MSEK (-5.0 MSEK)
∞∞Cash and cash equivalents on the balance day amounted to 14.4 MSEK (8.3 MSEK)
∞∞Shareholder’s equity per June 30, 2019 amounted to 84.7 MSEK (108.9 MSEK)